Skip to main content

Cancer: Drugs

Question for Department of Health and Social Care

UIN 3710, tabled on 17 May 2022

To ask the Secretary of State for Health and Social Care, what assessment he has been made of the adequacy of access for stage 4 cancer patients to (a) Evashield and (b) other drugs that help increase resistance to covid-19.

This answer is the replacement for a previous holding answer.

Answered on

7 June 2022

Patients with active metastatic cancer are eligible for novel antiviral and antibody treatment in the community through the COVID Medicine Delivery Units. The Medicines and Healthcare products Regulatory Agency highlighted the uncertainty of the appropriate dose of pre-exposure prophylactic medications, such as Evusheld, for protection against the Omicron variant. Understanding the efficacy of these treatments is necessary prior to any procurement or deployment. The UK Health Security Agency is currently undertaking further testing on Evusheld’s effectiveness against the Omicron variant. This will inform any decisions on the procurement of this treatment.

Named day
Named day questions only occur in the House of Commons. The MP tabling the question specifies the date on which they should receive an answer. MPs may not table more than five named day questions on a single day.